CASI Pharmaceuticals (CASIF) Return on Capital Employed (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Return on Capital Employed came in at 444.36% in Q4 2025, up 62289.0% YoY from N/an in Q4 2024, and up 14.2% on a QoQ basis from 389.12% in Q3 2025.
CASI Pharmaceuticals (CASIF) Return on Capital Employed (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Return on Capital Employed data on file, last reported at 444.36% in Q4 2025.
- Quarterly Return on Capital Employed rose 62289.0% year-over-year to 444.36% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 444.36% (up 62289.0% YoY) and the FY2025 annual result came in at 449.71%, up 59112.0% from the prior year.
- Return on Capital Employed improved to 444.36% in Q4 2025, from 389.12% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 444.36% in Q4 2025 to a low of 178.53% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 444.36% |
| Sep 30, 2025 | 389.12% |
| Jun 30, 2025 | 193.90% |
| Mar 31, 2025 | 0.12% |
| Dec 31, 2024 | -178.53% |
| Jun 30, 2024 | 0.28% |
| Mar 31, 2024 | -47.03% |